PMID- 3149495
OWN - NLM
STAT- MEDLINE
DCOM- 19890530
LR  - 20190718
IS  - 0269-9370 (Print)
IS  - 0269-9370 (Linking)
VI  - 2
IP  - 6
DP  - 1988 Dec
TI  - A new second-generation anti-HIV-1 enzyme immunoassay using recombinant envelope 
      and core proteins.
PG  - 477-80
AB  - In a multicenter collaborative study a new second-generation HIV-1 antibody 
      enzyme immunoassay (Abbott recombinant HIV-1 EIA) using Escherichia 
      coli-expressed recombinant p24 and p41 proteins as solid-phase antigens was 
      compared with the first-generation H9 cell-line-based Abbott HIV-1 EIA. The 
      results of the confirmatory assays (Western blot, immunofluorescence), combined 
      with clinical information, were used as the reference standard for the detection 
      of HIV-1 antibodies in 10,676 random blood donor serum specimens, in a panel of 
      840 specimens from symptomatic and asymptomatic patients and a total of 63 serial 
      blood specimens from 23 people at risk. With fresh blood donor sera, the 
      specificity of the first-generation assay ranged between 99.54 and 99.76% (95% 
      confidence limits, CL) compared with 99.81-99.95% (95% CL) for the 
      second-generation EIA. With panel specimens the recombinant HIV-1 EIA achieved an 
      overall sensitivity of 100% and a specificity range of 98.3-99.7% (95% CL); the 
      corresponding sensitivity and specificity ranges observed for the 
      first-generation EIA were 98.0-99.5% (95% CL) and 94.3-96.8% (95% CL), 
      respectively. The improved sensitivity for the second-generation assay was 
      confirmed by testing serial samples from seroconverting patients. The use of 
      recombinant proteins eliminated non-specific reactions due to class II human 
      leukocyte antigen (HLA)-directed antibodies.
FAU - Backer, U
AU  - Backer U
AD  - Red Cross Blood Donor Service, Bavarian Red Cross, Munich, FRG.
FAU - Gathof, A
AU  - Gathof A
FAU - Howe, J
AU  - Howe J
FAU - Strobel, E
AU  - Strobel E
FAU - Deinhardt, F
AU  - Deinhardt F
FAU - Gurtler, L
AU  - Gurtler L
FAU - Grob, P
AU  - Grob P
FAU - Joller-Jemelka, H
AU  - Joller-Jemelka H
FAU - Kuhnl, P
AU  - Kuhnl P
FAU - Seidl, S
AU  - Seidl S
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (HIV Antibodies)
RN  - 0 (HIV Antigens)
RN  - 0 (HIV Core Protein p24)
RN  - 0 (HIV Envelope Protein gp41)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Retroviridae Proteins)
RN  - 0 (Viral Envelope Proteins)
SB  - IM
MH  - Blood Donors
MH  - Diagnostic Errors
MH  - HIV Antibodies/*analysis
MH  - HIV Antigens/immunology
MH  - HIV Core Protein p24
MH  - HIV Envelope Protein gp41
MH  - HIV Seropositivity/prevention & control
MH  - HIV-1/*immunology
MH  - Humans
MH  - *Immunoenzyme Techniques
MH  - Mass Screening
MH  - Multicenter Studies as Topic
MH  - Recombinant Proteins/immunology
MH  - Retroviridae Proteins/immunology
MH  - Viral Envelope Proteins/immunology
EDAT- 1988/12/01 00:00
MHDA- 1988/12/01 00:01
CRDT- 1988/12/01 00:00
PHST- 1988/12/01 00:00 [pubmed]
PHST- 1988/12/01 00:01 [medline]
PHST- 1988/12/01 00:00 [entrez]
AID - 10.1097/00002030-198812000-00011 [doi]
PST - ppublish
SO  - AIDS. 1988 Dec;2(6):477-80. doi: 10.1097/00002030-198812000-00011.